PacBio, a number one developer of high-quality, extremely correct sequencing options, introduced right this moment that Bioscientia is utilizing its Revio long-read sequencing system to broaden its genomics analysis initiatives and sequence a number of thousand human genomes per yr. A part of Sonic Healthcare Group, Bioscientia is a number one world supplier of scientific laboratory testing companies for diagnostics primarily based in Germany. The elevated accuracy, learn size and methylation insights provided by the Revio system will allow Bioscientia to discover sure monogenic issues, comparable to deafness, blindness, and developmental delay, and research the underlying causes of uncommon illnesses.
Picture Credit score: PacBio
“Bioscientia is a world-leading supplier of testing companies, and we’re thrilled that they’ve chosen Revio to discover the potential scientific use of long-read sequencing,” mentioned Christian Henry, President and Chief Govt Officer of PacBio. “Revio will assist allow Bioscientia to ship extra insights to households with fewer assessments, decrease general prices, and fewer time spent assembling genome maps. This analysis is important for advancing our understanding of the position genetics performs in uncommon illnesses and developmental issues. Working with firms like Bioscientia is a crucial step in reaching PacBio’s mission to allow the promise of genomics to higher human well being.”
Complete-genome sequencing utilizing the Revio system allows the consolidation of a number of assessments right into a single, complete resolution, changing the time-consuming and expensive multi-stage vetting course of for uncommon illnesses and developmental delay issues. Beforehand, separate experiments like chromosome evaluation, optical genome mapping, and short-read exome sequencing have been required. By leveraging Revio expertise, researchers can now receive very important knowledge quicker and extra effectively. This development helps to scale back prices, enhance accessibility, and provide hope for households to higher perceive the genetic underpinning of sure uncommon illnesses, probably reworking the panorama of uncommon illness analysis and developmental delay evaluation.
“Revio will allow us to reply questions we beforehand couldn’t clear up with simply exome sequencing – serving to us to deal with many unsolved or partially solved instances,” commented Professor Hanno Bolz, MD, Head of Human Genetics at Bioscientia. “Buying these new Revio techniques will considerably broaden Bioscientia’s genomics capabilities. Outcomes that beforehand required a number of assessments can now be accomplished in a single run with Revio. Haplotype phasing is feasible on a person pattern, and not requires familial segregation evaluation. HiFi reads cowl repetitive areas, genes with pseudogene backgrounds and permit for methylation evaluation – so we are able to uncover imprinting defects. We imagine this expertise will profit households by giving better readability in underlying causes of illnesses and, finally, shortening the diagnostic odyssey they face.”
Bioscientia can even use Revio for prolonged testing of partially solved samples and recessive illness eventualities. These are conditions the place Bioscientia’s present short-read exome sequencing applied sciences haven’t been in a position to present extra full, definitive explanations. HiFi sequencing gives a extremely correct full sequence of the genome, which means that structural variations and even “hidden” gene mutations in advanced and difficult-to-sequence areas are recognized with better confidence.
Bioscientia has been a pioneer of innovation in advanced diagnoses for greater than 50 years, and we look ahead to serving to it advance its mission. PacBio’s sequencing applied sciences are among the many most correct and full accessible right this moment. Mixed with advances in throughput and value, we imagine Revio will empower the Bioscientia group to additional speed up its field-leading analysis throughout many functions in genomics.”
Jeff Eidel, Chief Business Officer, PacBio
